Rubicon Research
Rubicon Research Share Price Chart
Rubicon Research last traded at ₹1,547.10 (2026-10-13). Over the past month the stock moved -14.0%, three months the stock moved +58.2%. Its closing range over 52 weeks is ₹577.25 – ₹1,861.15, with the latest close 16.9% below the high.
Closing prices up to 2026-10-13.
About Rubicon Research
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]
Business Profile[1] Rubicon Research Limited is a formulation-focused pharmaceutical company focusing predominantly on the United States. The company has established a strong presence in the US generic and specialty drug market, which contributed 99.5% of its revenue in Q1 FY26.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Rubicon Research reported sales of ₹534.00 crore (+51.7%) and net profit of ₹85.00 crore (+97.7%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 534.00 | 129.00 | 24.00 | 85.00 | 5.13 |
| Mar 2026 | 514.00 | 119.00 | 23.00 | 77.00 | 4.65 |
| Dec 2025 | 476.00 | 108.00 | 23.00 | 73.00 | 4.42 |
| Sep 2025 | 412.00 | 94.00 | 23.00 | 54.00 | 3.49 |
| Jun 2025 | 352.00 | 79.00 | 22.00 | 43.00 | 2.81 |
| Mar 2025 | 358.00 | 72.00 | 20.00 | 36.00 | 2.35 |
| Dec 2024 | 313.00 | 70.00 | 22.00 | 38.00 | 2.50 |
| Sep 2024 | 296.00 | 62.00 | 21.00 | 34.00 | 2.27 |
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales growth | +39.2% | +52.1% | +43.6% | +51.7% |
| Operating profit growth | +51.6% | +54.3% | +65.3% | +63.3% |
| Net profit growth | +58.8% | +92.1% | +113.9% | +97.7% |
| EPS growth | +53.7% | +76.8% | +97.9% | +82.6% |
| OPM % | 23.0% | 23.0% | 23.0% | 24.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Rubicon Research reported sales of ₹1,754.00 crore (+36.6%) and net profit of ₹247.00 crore (+84.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1,754 | 400.00 | 23.00 | 247.00 | 14.98 |
| Mar 2025 | 1,284 | 264.00 | 21.00 | 134.00 | 8.72 |
| Mar 2024 | 854.00 | 155.00 | 18.00 | 91.00 | 5.98 |
| Mar 2023 | 394.00 | 18.00 | 5.00 | -17.00 | -33.31 |
| Mar 2022 | 314.00 | -39.00 | -12.00 | -67.00 | -132.39 |
| Mar 2021 | 315.00 | 92.00 | 29.00 | 31.00 | 60.53 |
| Mar 2020 | 263.00 | 81.00 | 31.00 | 49.00 | 97.46 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales growth | +19.8% | -0.3% | +25.5% | +116.8% | +50.4% | +36.6% |
| Operating profit growth | +13.6% | -142.4% | – | +761.1% | +70.3% | +51.5% |
| Net profit growth | -36.7% | -316.1% | – | – | +47.3% | +84.3% |
| EPS growth | -37.9% | -318.7% | – | – | +45.8% | +71.8% |
| OPM % | 29.0% | -12.0% | 5.0% | 18.0% | 21.0% | 23.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Rubicon Research.
Get Free AI Stock Analysis FREE →Latest News
-
USFDA completes unannounced inspection at Rubicon Research’s Satara facility
-
USFDA completes unannounced inspection at Rubicon Research’s Satara facility
-
USFDA completes unannounced inspection at Rubicon Research’s Satara facility
-
USFDA completes unannounced inspection at Rubicon Research’s Satara facility
-
USFDA completes unannounced inspection at Rubicon Research’s Satara facility
-
Rubicon Research zooms 166% in CY2026; hits new high post Q1 results - Business Standard
-
Rubicon Research zooms 166% in CY2026; hits new high post Q1 results - Business Standard
-
Rubicon Research soars on acquiring manufacturing facility in New Jersey, US
-
Rubicon Research zooms 128% so far in 2026; what's driving pharma stock? - Business Standard
-
Rubicon Research receives two procedural observations after USFDA inspection - Business Standard
Frequently Asked Questions
What is the share price of Rubicon Research today?
Rubicon Research shares were last quoted at ₹1,547.10 (-0.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Rubicon Research?
Rubicon Research has a price-to-earnings (P/E) ratio of 96.33 and a price-to-book (P/B) ratio of 20.21. The industry P/E is 53.33.
What is the 52-week high and low of Rubicon Research?
The 52-week high of Rubicon Research is ₹1,896.15 and the 52-week low is ₹571.00.
What is the market cap of Rubicon Research?
The market capitalisation of Rubicon Research is about ₹27,762.18 crore.
How did Rubicon Research perform in its latest quarterly results?
In the latest quarter (Jun 2026), Rubicon Research reported sales of ₹534.00 crore (+51.7%) and net profit of ₹85.00 crore (+97.7%), compared with the same quarter last year.
Is Rubicon Research a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Rubicon Research has a 3-year ROE of 27.00%, 3-year profit growth of 155.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Rubicon Research?
Promoters hold about 59.76% of Rubicon Research.
Which sector does Rubicon Research belong to?
Rubicon Research belongs to the Pharmaceuticals & Drugs sector.